利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.037 秒)

    COMPOSITIONS AND METHODS FOR UPREGULATING HIPPOCAMPAL PLASTICITY AND HIPPOCAMPUS-DEPENDENT LEARNING AND MEMORY
    1.
    发明公开
    COMPOSITIONS AND METHODS FOR UPREGULATING HIPPOCAMPAL PLASTICITY AND HIPPOCAMPUS-DEPENDENT LEARNING AND MEMORY 审中-公开
    组合物和高度调节的海马可塑性和海马依赖的学习和记忆方法

    公开(公告)号：EP3024467A2

    公开(公告)日：2016-06-01

    申请号：EP14828920.0

    申请日：2014-07-23

    申请人： Revalesio Corporation

    发明人： WATSON, Richard L. ,  WOOD, Anthony B. ,  ARCHAMBEAU, Gregory J. ,  GHOSH, Supurna

    IPC分类号： A61K33/00 ,  A61K9/00 ,  A61K31/58 ,  A61P25/28

    CPC分类号： A61K9/51 ,  A61K9/08 ,  A61K33/00 ,  A61K45/06 ,  A61K2300/00

    摘要： Provided are methods for enhancing hippocampal plasticity and hippocampal-mediated learning and memory, and/or enhancing the synaptic maturation of neurons, and/or optimizing or enhancing neuronal synaptic transmission, and/or enhancing intracellular oxygen delivery or utilization, and/or enhancing ATP synthesis, comprising administration, to a subject in need thereof of a sufficient amount over a sufficient time, of an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures (e.g., nanobubbles) having an average diameter of less than 100 nm (e.g., in at least one subject group selected from but not limited to normal subjects, subjects recovering from neurological trauma (e.g., accidents or injury to the brain, stroke, oxygen deprivation, drowning, and asphyxia), and subjects with learning disorders (e.g., dyslexia, dyscalculia, dysgraphia, dyspraxia (sensory integration disorder), dysphasia/aphasia, auditory processing disorder, non-verbal learning disorder, visual processing disorder, and attention deficit disorder (ADD)).

    BACTERIOSTATIC OR BACTERIOCIDAL COMPOSITIONS AND METHODS
    3.
    发明公开
    BACTERIOSTATIC OR BACTERIOCIDAL COMPOSITIONS AND METHODS 审中-公开
    抑菌或杀菌组合物和方法

    公开(公告)号：EP2207669A1

    公开(公告)日：2010-07-21

    申请号：EP08842668.9

    申请日：2008-10-23

    申请人： REVALESIO CORPORATION

    发明人： WATSON, Richard L. ,  WOOD, Anthony B. ,  ARCHAMBEAU, Gregory J.

    IPC分类号： B32B5/02 ,  B32B27/04

    CPC分类号： C12N13/00 ,  A61K33/00 ,  A61K45/06

    摘要： Particular aspects provide compositions and methods for treating or preventing bacterial infection or at least one symptom related to bacterial infection, and the like in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically generated fluid (including gas-enriched electrokinetically generated fluids) as disclosed herein, the electrokinetically altered aqueous fluid suitable to alter cellular membrane structure or function sufficient to provide for modulation of intracellular signal transduction, wherein treating bacterial infection or at least one symptom related to bacterial infection is thereby afforded. In particular embodiments, the fluids are gas-enriched fluids or therapeutic compositions and methods, and include oxygen-enriched water optionally in combination with other therapeutic agents. Other embodiments include particular routes of administration or formulations for the gas-enriched therapeutic compositions.

    COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE
    4.
    发明公开
    COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE 审中-公开
    组合物和治疗心血管疾病的方法

    公开(公告)号：EP2603199A1

    公开(公告)日：2013-06-19

    申请号：EP11817151.1

    申请日：2011-08-12

    申请人： Revalesio Corporation

    发明人： WATSON, Richard L. ,  WOOD, Anthony B. ,  ARCHAMBEAU, Gregory J.

    IPC分类号： A61K9/00

    CPC分类号： A61K33/00 ,  A61K9/0009 ,  A61K9/0019 ,  A61K9/08 ,  A61K31/58 ,  A61K33/40 ,  A61K2300/00

    摘要： Provided are methods for treating cardiovascular diseases and related conditions and symptoms (e.g., cardiac arrhythmia, vascular disease, myocardial infarction, congestive heart failure, myocarditis, atherosclerosis, and restenosis), comprising administering to a subject in need thereof a therapeutically effective amount of an electrokinetically altered aqueous fluid as described herein. In particular aspects, the electrokinetically altered aqueous fluids comprise an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures predominantly having an average diameter of less than about 100 nanometers and sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity. Provided are routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions, along with use of the electrokinetically altered aqueous fluids in surgical contexts, including but not limited to cardiovascular related surgeries. Additionally provided are methods for measuring biological activity of electrokinetically altered fluids.

    摘要翻译： 所提供的是用于治疗心血管疾病和相关病症和症状（例如心律失常，血管疾病，心肌梗塞，充血性心力衰竭，心肌炎，动脉粥样硬化和再狭窄）的方法，其包括向有需要的受试者施用治疗有效量的 如本文所述的电动改变的含水流体。 在特定方面，电动改变的含水流体包含电荷稳定的含氧纳米结构的离子水溶液，其主要具有小于约100纳米的平均直径并且足以提供对细胞膜电位和细胞膜电导率中的至少一种的调节 。 提供用于电动改变的流体（例如，电动改变的富含气体的流体和溶液）和治疗组合物的施用途径或制剂，以及在手术环境中使用电动改变的水性流体，包括但不限于心血管相关 手术。 另外提供了用于测量电动改变流体的生物活性的方法。

    COMPOSITIONS AND METHODS FOR MODULATING CELLULAR MEMBRANE-MEDIATED INTRACELLULAR SIGNAL TRANSDUCTION
    9.
    发明公开
    COMPOSITIONS AND METHODS FOR MODULATING CELLULAR MEMBRANE-MEDIATED INTRACELLULAR SIGNAL TRANSDUCTION 审中-公开
    调制细胞膜组合物和方法介导的细胞内信号重发

    公开(公告)号：EP2215260A1

    公开(公告)日：2010-08-11

    申请号：EP08842968.3

    申请日：2008-10-23

    申请人： REVALESIO CORPORATION

    发明人： WATSON, Richard L. ,  WOOD, Anthony B. ,  ARCHAMBEAU, Gregory J.

    IPC分类号： C12Q1/68 ,  C12N5/00

    CPC分类号： C12N13/00 ,  A61K31/137 ,  A61K31/58 ,  A61K31/7036 ,  A61K33/00 ,  A61K33/14 ,  A61K45/06 ,  G01N33/6872 ,  A61K2300/00

    摘要： Particular aspects of the present invention provide compositions and methods for modulating intracellular signal transduction, including modulation of at least one of membrane structure, membrane potential or membrane conductivity, membrane proteins or receptors, ion channels, and calcium dependant cellular messaging systems, comprising use of the inventive electrokinetically generated solutions to impart electrochemical and/or conformational changes in membranous structures (e.g., membrane and/or membrane proteins, receptors or other components) including but not limited to G-protein coupled receptors (GPCRs) and/or G-proteins, and intracellular junctions. In particular embodiments, the electrokinetically generated solutions or compositions are gas-enriched and/or comprise other therapeutic agents. Other embodiments include particular therapeutic methods comprising administration or formulations of the therapeutic compositions, and in various combination treatments.

    COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND LUNG DISORDERS
    10.
    发明公开
    COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND LUNG DISORDERS 有权
    组合物和方法治疗哮喘和肺病

    公开(公告)号：EP2214712A1

    公开(公告)日：2010-08-11

    申请号：EP08841984.1

    申请日：2008-10-27

    申请人： REVALESIO CORPORATION

    发明人： WATSON, Richard L. ,  WOOD, Anthony B. ,  ARCHAMBEAU, Gregory J.

    IPC分类号： A61K45/00

    CPC分类号： C12N13/00 ,  A61K33/00 ,  A61K45/06

    摘要： Provided are compositions and methods for treating or preventing lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis (e.g. nose respiratory tract), and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically generated fluid (including gas-enriched electrokinetically generated fluids) as disclosed herein, the electrokinetically altered aqueous fluid suitable to alter cellular membrane structure or function sufficient to provide for modulation of intracellular signal transduction, wherein treating a lung disorder or a symptom thereof is thereby afforded. Additional aspects relate to therapeutic compositions, and combination treatment methods comprising administration of at least one electrokinetically generated fluid in combination with at least one additional therapeutic agent.